-
Mashup Score: 0Momelotinib Wins Canadian Approval for Myelofibrosis With Anemia - 5 hour(s) ago
Health Canada has approved momelotinib for the treatment of splenomegaly and/or disease-related symptoms in myelofibrosis with moderate-to-severe anemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Health Canada has approved momelotinib for the treatment of splenomegaly and/or disease-related symptoms in myelofibrosis with moderate-to-severe anemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Momelotinib Wins Canadian Approval for Myelofibrosis With Anemia #mpnsm #oncology https://t.co/LLD7HVjwQE
-
-
Mashup Score: 0Momelotinib Wins Canadian Approval for Myelofibrosis With Anemia - 10 day(s) ago
Health Canada has approved momelotinib for the treatment of splenomegaly and/or disease-related symptoms in myelofibrosis with moderate-to-severe anemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Momelotinib Wins Canadian Approval for Myelofibrosis With Anemia #mpnsm #oncology https://t.co/LLD7HVjwQE
-
-
Mashup Score: 0The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens - 15 day(s) ago
Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Daniel DeAngelo MD, PhD, noted that there has been a shift in management strategies for advanced follicular lymphoma towards newer agents such as lenalidomide plus rituximab and bispecific antibodies for early relapse. @DanaFarberNews #mpnsm #oncology https://t.co/4CVqCVS8p8 https://t.co/idBQMbqFF8
-
-
Mashup Score: 1JAK Inhibitors Remain the Gold Standard in Myelofibrosis - 18 day(s) ago
Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm. @DanaFarberNews #mpnsm #oncology https://t.co/cg4et5BlO6
-
-
Mashup Score: 0
Jorge Cortes, MD, discusses the need to balance outcomes and quality of life in the treatment of anemia in low-risk myelodysplastic syndrome.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
QOL Remains Key Consideration for First-Line Treatment of Anemia in Lower-Risk MDS @GCC_Cortes #mpnsm #oncology https://t.co/4hv3t7CN8L
-
-
Mashup Score: 1JAK Inhibitors Remain the Gold Standard in Myelofibrosis - 21 day(s) ago
Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm. @DanaFarberNews #mpnsm #oncology https://t.co/cg4et5BlO6
-
-
Mashup Score: 2
Jorge Cortes, MD, discusses the need to balance outcomes and quality of life in the treatment of anemia in low-risk myelodysplastic syndrome.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
QOL Remains Key Consideration for First-Line Treatment of Anemia in Lower-Risk MDS @GCC_Cortes #mpnsm #oncology https://t.co/4hv3t7CN8L
-
-
Mashup Score: 2
Jorge Cortes, MD, discusses the need to balance outcomes and quality of life in the treatment of anemia in low-risk myelodysplastic syndrome.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
QOL Remains Key Consideration for First-Line Treatment of Anemia in Lower-Risk MDS @GCC_Cortes #mpnsm #oncology https://t.co/4hv3t7CN8L
-
-
Mashup Score: 3Selinexor Paves the Way for More Affordable, Effective Treatment Options in Myelofibrosis - 28 day(s) ago
Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis. @DrJoeScandura @nyphospital #mpnsm #Oncology https://t.co/73JqfOALz4
-
Momelotinib Wins Canadian Approval for Myelofibrosis With Anemia #mpnsm #oncology https://t.co/LLD7HVjwQE